Amneal receives EU approval for omalizumab biosimilar

Amneal Pharmaceuticals (AMRX) received EU approval for Adcomfo, a biosimilar to XOLAIR. The approval covers treatments for severe allergic asthma, chronic rhinosinusitis, and chronic urticaria. Adcomfo was developed by Kashiv BioSciences, acquired by Amneal in August. The product is supported by clinical data and is marketed in Europe by ADVANZ PHARMA. AMRX's U.S. application is under FDA review.

Original reporting
Published Nov 17, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AMRX
Bullish
medium confidence
Mentioned
$AMRX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRXBullishMed
01

Why it matters

This is a regulatory de-risking event for AMRX’s biosimilar program in Europe, while U.S. commercialization remains contingent on FDA approval of its BLA.

02

Market read

Traders may reassess AMRX’s biosimilar probability-weighting and commercialization outlook after a fresh EU authorization, even as U.S. remains pending.

03

What to watch

The article notes ADVANZ Pharma holds EU commercialization rights and that the U.S. FDA BLA is still under review, so the biggest upside may depend on U.S. timing and partner economics rather than EU alone.

Relevance 8/10Novelty 8/10Timing: after-hours/overnight news flow for the next trading session

Background

Amneal’s Adcomfo is a biosimilar to XOLAIR (omalizumab) developed via collaboration and acquired through Kashiv BioSciences, with EU approvals already progressing.

Company-level read

Ticker impact

$AMRXBullishMedium confidence
Context

Amneal says the European Commission granted marketing authorization for its omalizumab biosimilar Adcomfo (Adcomfo), expanding EU commercial availability.

Expected impact

Likely positive bias as the market prices in improved probability of EU uptake and progress toward the still-pending U.S. approval.

Evidence & confidence

The article is a first-report regulatory approval in Europe for AMRX’s biosimilar, with defined indications, formulations, and a stated FDA BLA still under review, which typically improves forward commercialization expectations.

Market effects

Adds incremental competitive pressure in omalizumab biosimilars in Europe and reinforces the broader biosimilar approval pipeline narrative.

EU approval can shift payer and formulary dynamics for severe allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.

Supports global read-through for biosimilar timelines, especially as the U.S. FDA BLA is still pending.

Counterpoint

EU approval may not translate quickly into material revenue if uptake is slow, pricing is pressured, or ADVANZ Pharma’s commercialization execution limits near-term impact.

Key entities

  • Amneal Pharmaceuticals

    NASDAQ-listed company receiving EU marketing authorization for its omalizumab biosimilar Adcomfo.

  • Adcomfo (omalizumab)

    Amneal’s biosimilar to XOLAIR, approved for multiple add-on indications in Europe.

  • European Commission

    Granted marketing authorization for Adcomfo following a positive CHMP opinion.

  • ADVANZ PHARMA

    Holds EU marketing authorization and regional commercialization rights through partnership with Alvotech.

  • U.S. FDA

    BLA for Amneal’s proposed biosimilar to XOLAIR is currently under review.

Related articles

$AMRXHighAI 8/10

Amneal Earnings Call Signals Strong Growth Ahead

Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $863M, up 10% YoY, with adjusted EBITDA rising 30% to $207M and adjusted EPS increasing 53% to $0.26. The company raised its 2026 revenue outlook to $3.15B-$3.25B and adjusted EBITDA guidance to $800M-$815M. Growth was driven by specialty brands, the Kashiv acquisition, and biosimilar platforms, though management noted pressure from AvKARE and temporarily higher leverage.

$AMRXMed

Piper Sandler reiterates Amneal stock rating on earnings beat

Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.